The advertised price is the list price halved by a promotion
The compounded semaglutide card carries three things: a struck-through figure introduced by the words starting from, a lower figure in large type, and a line reading promotion, buy one month, get one month free. Divide the struck figure by two and you land within fifty cents of the advertised one.
That is not a hidden fact — the page prints every element of it. But it changes what the advertised number means. It is not a plan rate that will still be there next quarter. It is what the standing rate costs while a two-for-one offer runs, and the footnote adds that it also requires paying two months up front.
Our record carries both figures, because only one of them survives the promotion ending. The tirzepatide card is the tell: same design, same footnote, no struck anchor and no promotion. The two drugs are priced on different terms on the same site, and only one of them is discounted.
Longer commitments advertise higher starting prices
A rotating banner sits at the top of every page. The first slide quotes the promotional figure. The second quotes a higher one and says twelve-month plans available. The third quotes a higher one again and says six-month plans available.
Read those in order and the offer gets worse as the commitment gets longer, which is the opposite of every other multi-month ladder in this comparison. The most likely explanation is that the banner figures are ordinary plan rates and the headline is a promotional one, so they are not describing the same thing at all. The site does not say that anywhere.
This matters because the three numbers appear in the same strip, in the same typeface, one after another. A reader has no way to tell from the page which of them is the price of the thing they are about to buy.
The oral product does not say what it is
There is a fourth product here: a once-daily sublingual GLP-1, priced, with its own page. The card names no molecule. It says oral compounded GLP-1 and once-daily GLP-1 medication, and the body describes a sublingual formula.
The site's own navigation lists a microdosing oral compounded semaglutide as a separate item, so the unqualified one is not shorthand for it. Lower down the page a study on semaglutide is cited, which is a footnote about the drug class, not a statement about what is in the tablet.
Twelve of the ninety-five sellers here withhold the molecule behind a figure in one form or another, and this is that pattern in its narrower form: three products name their drug and the fourth does not. Ask before the first dose rather than after.
The FDA letter is about the picture on the page
The agency reviewed this site in December 2025 and wrote in February 2026. The finding is unusually specific. The compounded semaglutide and tirzepatide products displayed on the website showed the company's own brand on the pictured label, which the agency said suggested the company was the compounder of those drugs when in fact it is not.
A warning letter is a disclosure and not a finding of guilt, and this roster does not treat one as a reason to exclude a seller or to score it down. Fourteen of the ninety-five sellers here carry one. The letter number, the date and a link to the agency's own text sit on this row.
What is worth noting is what is still on the page today. The product copy carries the phrase describing the preparation as having the same active ingredient as two named brand drugs — a claim shape the agency has cited against several other sellers in this field, though not the one it cited here.
Who is behind it, and where it will serve you
The company names itself plainly and repeatedly: a technology company operating a patient management platform, working with two named physician practices, and stating in its own words that it does not provide medical or pharmacy services. That is a real disclosure and better than several sellers here manage.
It stops there. No individual clinician is named anywhere. No pharmacy is named — the Terms describe being matched with one of the partner pharmacies, which is a process rather than a name. Fifty-one of the ninety-five sellers here name nobody who prescribes.
On coverage the Terms say twice that certain services are only available in certain states and that you will be told when you get there. We read the homepage, three medication pages, the Terms and the opt-out notice, and found no list and no exclusion. Fifty-eight of the ninety-five sellers here publish no service area at all.
One genuinely clear statement: no commercial insurance is accepted, the affiliated practices are not in network anywhere, and they are not enrolled with Medicare or Medicaid. That removes an ambiguity most sellers leave hanging.
Alan Meds's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $158/moPer month, and conditional twice over: "Starting from $315 $158 /mo* / PROMOTION: Buy 1 month, get 1 month free", with the card footnote "*Paid upfront with a 2-month plan. Actual price to the consumer will depend on the plan purchased." ⛔ $315 ÷ 2 = $157.50, so this figure is the list rate under a two-for-one offer, not a plan price. | September 2026source |
| Semaglutide (compounded) | $315/moThe struck-through "Starting from" figure printed beside the promotional rate on the same card — the number the seller itself names as the price without the buy-one-get-one offer. Recorded because it is the figure that outlives the promotion. | September 2026source |
| Tirzepatide (compounded) | $325/mo"Personalized Compounded Tirzepatide / Starting from / $325 /mo*", with the same footnote about a prepaid plan. ⛔ No struck-through anchor and no promotion appear on this card, so the two-for-one offer that halves the semaglutide headline does not apply here — the drugs are priced on different terms on the same site. | September 2026source |
| Glp-1 (compounded-oral) | $215/mo"Oral Compounded GLP-1 / Starting from / $305 $215 /mo*", footnoted "*Paid upfront with a 6-month plan." A six-month prepayment stands behind the lower figure and the struck $305 is the unprepaid rate. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 95 providers reviewed here are paid partners today; the other 91 are not. See how this works.
See Alan Meds's current price →Good fit if
- Readers who want four GLP-1 formats — injection, oral, microdose and a brand route — priced on one site without an intake.
- Buyers who will compare on the struck-through list figures rather than the promotional ones, and who can see why that matters here.
- People who want the plan term printed in a footnote under the figure rather than discovered at checkout.
- Anyone who wants the operating company and its affiliated physician practices named outright.
Look elsewhere if
- Anyone treating the headline as a standing rate. It is the card's own list price halved by a two-for-one promotion, and it also requires a two-month prepayment.
- Readers who need to know which molecule they are taking. The oral product names no drug on its own card while a separate menu item names one.
- Buyers who want the compounding pharmacy or an individual prescriber named. Neither appears anywhere here.
- Anyone who needs their state confirmed before starting. The Terms decline to list, twice.
- Readers for whom an open FDA enforcement action against the operating company is a filter.
How this review was verified
- Re-read the homepage, the compounded semaglutide page, the compounded tirzepatide page, the oral GLP-1 page, the Terms and the opt-out notice on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller.
- Computed the relationship between the struck figure and the advertised one rather than describing the promotion in the seller's words: the advertised rate is the struck rate divided by two, to within fifty cents.
- Printed the status, byte size and effective URL of every fetch and compared the effective path to the requested one. That is how we found that the weight-loss path returns a different page than the one requested, and it is why the source URLs on this row are the paths that actually serve the cards.
- Ran a nonsense path against this host in the same run as every read. It returned 404 — with a body of more than a hundred thousand bytes and nearly seven thousand characters of rendered shell text, which is exactly why nothing here was judged by size.
- Extracted every figure from a Python html.parser pass over text nodes only, with inline siblings joined so a price split across element boundaries still reads as one string, and residual markup asserted absent.
- Counted the molecule references on the oral product page rather than assuming: the card and its description name no drug, and the site's own menu lists an oral semaglutide as a different product.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. The letter returned is recorded on this row with its number, date and link; a nonsense warning-letter path on the same host returned 404 in the same run. Untitled letters are published separately and were not searched.